BeiGene's BGB-3111 produces Phase I responses

Data from an abstract released ahead of the American Society of Hematology (ASH) meeting showed BGB-3111 from BeiGene Ltd. (Beijing, China) produced an objective response in 64% of patients in an interim analysis of a Phase I study to treat relapsed-refractory B cell malignancies.

The data are the first human results for the company's highly selective oral Bruton's tyrosine kinase (Btk) inhibitor. ...